GRAL · GRAIL, Inc.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $165.26M | $147.17M | $125.6M | $93.11M | $55.55M | |
| $190.99M | $195.79M | $322.38M | $338.75M | $329.58M | |
| $121.5M | $116.69M | $153.96M | $162.29M | $122.33M | |
| $169.59M | $159.1M | $213.86M | $200.27M | $174.11M | |
| $133.89M | $133.89M | $133.89M | $133.89M | $138.33M | |
| $724.51M | $709.34M | $2.31B | $1.61B | $5.5B | |
| -$559.25M | -$562.16M | -$2.19B | -$1.52B | -$5.44B | |
| — | -381.98% | -1743.03% | -1627.61% | -9798.18% | |
| $29.28M | $28.65M | $26.73M | $7.95M | $1.74M | |
| $29.78M | $27.66M | $26.8M | $7.75M | $1.5M | |
| -$529.47M | -$534.5M | -$2.16B | -$1.51B | -$5.44B | |
| -$137.88M | -$126.15M | -$135.36M | -$41.95M | -$42.29M | |
| -$391.59M | -$408.35M | -$2.03B | -$1.47B | -$5.4B | |
| — | -277.47% | -1613.92% | -1574.23% | -9719.35% | |
| -$392.05M | -$407.15M | -$2.03B | -$1.47B | -$5.4B | |
| USD/shares | -$9.68 | -$11.11 | -$63.54 | -$47.21 | -$173.89 |
| USD/shares | -$9.68 | -$11.11 | -$63.54 | -$47.21 | -$173.89 |
| shares | — | 36.75M | 31.9M | 31.05M | 31.05M |
| shares | — | 36.75M | 31.9M | 31.05M | 31.05M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 22 similar-size Diagnostics & Research companies (of 46 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| United States | $137,093,000 | $110,816,000 | $78,679,000 | — |
| Non Us | $10,079,000 | $14,779,000 | $14,426,000 | $12,188,000 |
| Americas | — | — | — | $43,362,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Screening Revenue | $138,601,000 | $108,627,000 | $74,999,000 | $39,817,000 |
| Developmental Services Revenue | $8,571,000 | $16,968,000 | $18,106,000 | $15,733,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | -$562,163,000 | -$2,189,158,000 | -$1,515,382,000 | -$5,442,890,000 |